Elanco Q1 revenue +15% to $1.37B, raises FY2026 guidance across all metrics

Elanco Animal Health Inc

2026-Q1 EPS reported $0.11 revenue$1,371,000,000

Q1 revenue $1.37B (+15% reported, +10% organic constant currency); adjusted EPS $0.40 vs $0.37 prior year.
Full-year 2026 guidance raised: revenue $5,010-$5,085M, adj. EBITDA $975-$1,005M, adj. EPS $1.03-$1.09.
Q2 2026 guidance: revenue $1,300-$1,325M, adj. EBITDA $240-$260M, adj. EPS $0.25-$0.28.
Innovation revenue target raised to $1.2B; net leverage target improved to 3.0x-3.2x.
Credelio Quattro and Zenrelia post strong share gains; closed AHV International acquisition Apr 30.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Elanco Animal Health Inc reported first quarter of 2026 results: revenue $1,371 million, net income $57 million, EPS $0.11. Guidance raised.

Period: first quarter of 2026
Revenue: $1,371 million
Net income: $57 million
EPS: $0.11
Guidance: raised
Result: reported results

Exact text from the filing

First Quarter 2026 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target • First Quarter 2026 Financial Results: ◦ Revenue of $1,371 million, an increase of 15% year-o ver-ye ar; 10% organic constant currency growth ◦ Reported Net Income of $57 million, Adjusted Net Income of $204 million ◦ Adjusted EBITDA of $334

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

Elanco Animal Health Inc filing history →

Source: SEC EDGAR

accession 0001739104-26-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.